Sign In
Buy OBSV
$0.102
+0 (+0%)
At Close: Jun 21, 2023
ObsEva SA to present at the SVB LEERINK 9th Annual Global Healthcare Conference February 26th 2020
06:00am, Tuesday, 18'th Feb 2020
Geneva, Switzerland and Boston, MA – February 18, 2019 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to.
Obseva SA to Post Q1 2020 Earnings of ($0.59) Per Share, Svb Leerink Forecasts (NASDAQ:OBSV)
07:16am, Thursday, 30'th Jan 2020
Obseva SA (NASDAQ:OBSV) – Svb Leerink issued their Q1 2020 earnings estimates for Obseva in a research report issued on Monday, January 27th. Svb Leerink analyst A. Fadia forecasts that the company
Health Check: How Prudently Does ObsEva (NASDAQ:OBSV) Use Debt?
02:34pm, Wednesday, 22'nd Jan 2020
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Wedbush Remains a Buy on ObsEva SA (OBSV)
02:46pm, Tuesday, 21'st Jan 2020
Wedbush analyst
Liana Moussatos
reiterated a
Buy
rating on ObsEva SA (
OBSV
–
Research Report
) today and set a price target of
$36.00
. The company’s shares closed last Monday at $3.95, close to
H.C. Wainwright Remains a Buy on ObsEva SA (OBSV)
12:24pm, Tuesday, 21'st Jan 2020
H.C. Wainwright analyst
Ram Selvaraju
reiterated a
Buy
rating on ObsEva SA (
OBSV
–
Research Report
) today and set a price target of
$40.00
. The company’s shares closed last Monday at $3.80, clo
Could ObsEva SA’s (NASDAQ:OBSV) Investor Composition Influence The Stock Price?
06:07pm, Monday, 20'th Jan 2020
The big shareholder groups in ObsEva SA (NASDAQ:OBSV) have power over the company. Insiders often own a large chunk of...
Wedbush Securities Inc. Increases Holdings in Obseva SA (NASDAQ:OBSV)
10:16am, Monday, 20'th Jan 2020
Wedbush Securities Inc. raised its stake in shares of Obseva SA (NASDAQ:OBSV) by 242.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commi
Analysts Suggest Picking Up These 2 Falling Knives
04:27pm, Thursday, 16'th Jan 2020
Their moderate to low financial burden reduces the investment risk Continue reading...
FY2024 Earnings Estimate for Obseva SA Issued By Wedbush (NASDAQ:OBSV)
08:38am, Thursday, 16'th Jan 2020
Obseva SA (NASDAQ:OBSV) – Stock analysts at Wedbush issued their FY2024 earnings per share (EPS) estimates for shares of Obseva in a note issued to investors on Monday, January 13th. Wedbush analyst
ObsEva to Outline Corporate Plans For 2020 and Beyond at JP Morgan Healthcare Conference in San Francisco
06:00am, Wednesday, 15'th Jan 2020
ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced it will provide corporate plan
Wedbush Sticks to Their Buy Rating for ObsEva SA (OBSV)
12:49am, Tuesday, 14'th Jan 2020
Wedbush analyst Liana Moussatos reiterated a Buy rating on ObsEva SA (OBSV – Research Report) yesterday and set a price
DDD, NVTA among premarket gainers
02:27pm, Monday, 13'th Jan 2020
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) +56% as SPEAR T-cell platform delivers initial responses in four solid tumors.Verona Pharma PLC (NASDAQ:VRNA) +54% on positive ensifentrine data.Mereo BioP
ObsEva up 7% premarket on Nolasiban deal in China
12:22pm, Monday, 13'th Jan 2020
ObsEva (NASDAQ:OBSV) and Yuyuan BioScience Technology have entered into a sublicense agreement to develop and commercialize nolasiban for improving clinical pregnancy and live birth rates in women un
ObsEva and Yuyuan BioScience Technology (“Yuyuan”) today announced that they have entered into a sublicense agreement to develop and commercialize nolasiban for improving clinical pregnancy and li
Catabasis (CATB) Partners with UK-Based Charity for DMD Study
09:09pm, Thursday, 09'th Jan 2020
Catabasis (CATB) teams up with Duchenne UK to fund a phase II study of its pipeline candidate edasalonexent, now being developed to treat patients with non-ambulatory Duchenne muscular dystrophy.
